Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

NCT04196231 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

258

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: IDegLira
DRUG: IGlarLixi
DRUG: Insulin/Canaglifozin
DRUG: Insulin/Dapaglifozin
DRUG: Insulin/Empaglifozin
DRUG: Basal Bolus

Sponsor

University of Campania Luigi Vanvitelli